Cetrorelix Acetate Patent Expiration
Cetrorelix Acetate is Used for preventing premature LH surges in women undergoing controlled ovarian stimulation. It was first introduced by Emd Serono Inc
Cetrorelix Acetate Patents
Given below is the list of patents protecting Cetrorelix Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Cetrotide | US6319192 | Method for the treatment of fertility disorders |
Apr 23, 2019
(Expired) | Emd Serono Inc |
| Cetrotide | US6863891 | Oligopeptide lyophilisate, their preparation and use |
Feb 22, 2014
(Expired) | Emd Serono Inc |
| Cetrotide | US7605121 | Oligopeptide lyophilisate, their preparation and use |
Feb 22, 2014
(Expired) | Emd Serono Inc |
Try Our Curated Drug Screens
Cetrorelix Acetate Generics
Several generic applications have been filed for Cetrorelix Acetate. The first generic version for Cetrorelix Acetate was by Teva Pharmaceuticals Inc and was approved on Aug 12, 2022. And the latest generic version is by Gland Pharma Ltd and was approved on Apr 25, 2024.
Given below is the list of companies who have filed for Cetrorelix Acetate generic.
1. GLAND
Gland Pharma Ltd has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Gland.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/VIAL | powder | Prescription | SUBCUTANEOUS | AP | Apr 25, 2024 |
2. LIVZON GRP
Livzon Group Pharmaceutical Factory has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Livzon Grp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/VIAL | powder | Prescription | SUBCUTANEOUS | AP | Apr 24, 2024 |
3. QILU
Qilu Pharmaceutical Co Ltd has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Qilu.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/VIAL | powder | Prescription | SUBCUTANEOUS | AP | Apr 16, 2024 |
4. TEVA PHARMS INC
Teva Pharmaceuticals Inc has filed for 1 generic for Cetrorelix Acetate. Given below are the details of the strengths of this generic introduced by Teva Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.25MG BASE/VIAL | powder | Prescription | SUBCUTANEOUS | AP | Aug 12, 2022 |